Characterizing CDK12-Mutated Prostate Cancers.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published Date: Jan 15, 2021

Abstract

PURPOSE: Cyclin-dependent kinase 12 (CDK12) aberrations have been reported as a biomarker of response to immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). Herein, we characterize CDK12-mutated mCRPC, presenting clinical, genomic, and tumor-infiltrating lymphocyte (TIL) data.

Authors

  • Pasquale Rescigno
    The Institute of Cancer Research, Sutton, London, United Kingdom.
  • Bora Gurel
    The Institute of Cancer Research, Sutton, London, United Kingdom.
  • Rita Pereira
    The Institute of Cancer Research, Sutton, London, United Kingdom.
  • Mateus Crespo
    The Institute of Cancer Research, Sutton, London, United Kingdom.
  • Jan Rekowski
    The Institute of Cancer Research, Sutton, London, United Kingdom.
  • Mattia Rediti
    The Institute of Cancer Research, Sutton, London, United Kingdom.
  • Maialen Barrero
    The Institute of Cancer Research, Sutton, London, United Kingdom.
  • Joaquin Mateo
    Vall d'Hebron Institute of Oncology (VHIO) and Vall d'Hebron University Hospital, Barcelona, Spain.
  • Diletta Bianchini
    The Royal Marsden NHS Foundation Trust, Sutton, London, United Kingdom.
  • Carlo Messina
    The Institute of Cancer Research, Sutton, London, United Kingdom.
  • Maria D Fenor de la Maza
    The Institute of Cancer Research, Sutton, London, United Kingdom.
  • Khobe Chandran
    The Royal Marsden NHS Foundation Trust, Sutton, London, United Kingdom.
  • Juliet Carmichael
    The Institute of Cancer Research, Sutton, London, United Kingdom.
  • Christina Guo
    The Institute of Cancer Research, Sutton, London, United Kingdom.
  • Alec Paschalis
    The Institute of Cancer Research, Sutton, London, United Kingdom.
  • Adam Sharp
    The Institute of Cancer Research, Sutton, London, United Kingdom.
  • George Seed
    The Institute of Cancer Research, Sutton, London, United Kingdom.
  • Ines Figueiredo
    The Institute of Cancer Research, Sutton, London, United Kingdom.
  • Maryou Lambros
    The Institute of Cancer Research, Sutton, London, United Kingdom.
  • Susana Miranda
    The Institute of Cancer Research, Sutton, London, United Kingdom.
  • Ana Ferreira
    The Institute of Cancer Research, Sutton, London, United Kingdom.
  • Claudia Bertan
    The Institute of Cancer Research, Sutton, London, United Kingdom.
  • Ruth Riisnaes
    The Institute of Cancer Research, Sutton, London, United Kingdom.
  • Nuria Porta
    The Institute of Cancer Research, Sutton, London, United Kingdom.
  • Wei Yuan
    1 School of Mechanical Engineering, Tianjin University, Tianjin, China.
  • Suzanne Carreira
    The Institute of Cancer Research, Sutton, London, United Kingdom.
  • Johann S de Bono
    The Institute of Cancer Research, Sutton, London, United Kingdom. johann.de-bono@icr.ac.uk.

Keywords

External Resources

Popular Topics
Recent Journals